Last reviewed 2026-04-20 · How we verify

Questran

Albireo · FDA-approved active Small molecule

At a glance

Generic name	Questran
Sponsor	Albireo
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients (PHASE2)
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (PHASE3)
LATAM LOWERS LDL-C (PHASE4)
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies (PHASE1)
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer (PHASE1)
Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients (NA)
Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients (PHASE4)
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results